Sanford C. Bernstein set a €89.00 ($103.49) price objective on Bayer (FRA:BAYN) in a report published on Monday. The firm currently has a buy rating on the healthcare company’s stock.

BAYN has been the subject of several other reports. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on Bayer and gave the company a buy rating in a report on Thursday, June 21st. Cfra set a €100.00 ($116.28) price target on Bayer and gave the company a buy rating in a report on Tuesday, August 14th. Goldman Sachs Group set a €111.00 ($129.07) price target on Bayer and gave the company a buy rating in a report on Thursday, October 11th. Independent Research set a €85.00 ($98.84) target price on Bayer and gave the stock a neutral rating in a report on Wednesday, September 5th. Finally, Citigroup set a €100.00 ($116.28) target price on Bayer and gave the stock a buy rating in a report on Thursday, September 20th. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of €98.80 ($114.88).

Shares of Bayer stock opened at €77.38 ($89.98) on Monday. Bayer has a 52-week low of €91.58 ($106.49) and a 52-week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: How to Use a Moving Average for TradingĀ 

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.